Martine A Rothblatt sold $4.7M of UTHR
Chairperson & CEO at UNITED THERAPEUTICS Corp. 9,500 shares at an average of $494.83, traded Sep 22, 2026, filed Sep 23, 2026.
Score components
- +25RoleCEO
- +25Trade size$4.7M at market
- 0Share of holdings soldSold 2.8% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001106578-26-000147, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | MOption exercise Common Stockindirect: by Trust10b5-1 | +9,500 | $117.76 | $1.1M | 333,943 | 18 d ago |
| Sep 22, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -240 | $489.61 | $118k | 333,703 | 18 d ago |
| Sep 22, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -424 | $490.54 | $208k | 333,279 | 18 d ago |
| Sep 22, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -736 | $491.45 | $362k | 332,543 | 18 d ago |
| Sep 22, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -628 | $492.67 | $309k | 331,915 | 18 d ago |
| Sep 22, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -1,645 | $493.70 | $812k | 330,270 | 18 d ago |
| Sep 22, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -1,337 | $494.66 | $661k | 328,933 | 18 d ago |
| Sep 22, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -1,488 | $495.77 | $738k | 327,445 | 18 d ago |
| Sep 22, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -1,484 | $496.83 | $737k | 325,961 | 18 d ago |
| Sep 22, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -1,358 | $497.73 | $676k | 324,603 | 18 d ago |
| Sep 22, 2026 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -160 | $499.07 | $80k | 324,443 | 18 d ago |
| Sep 22, 2026 | MOption exercise Stock Optionderivativeindirect: by Trust10b5-1 | -9,500 | $0.00 | $0 | 385,410 | 18 d ago |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.5M 9,500 shares | -3% | |
| 18Weak | UNITED THERAPEUTICS Corp | Paul A Mahon EVP & GENERAL COUNSEL | $4.7M 8,300 shares | -16% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $3.9M 7,580 shares | -2% | |
| 38Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $1.1M 1,920 shares | -1% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.5M 9,500 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.